Displaying drugs 6951 - 6975 of 8030 in total
PAS-004
PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Investigational
Matched Description: … It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome. …
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide
9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour agents N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 9-amino-DACA.
Experimental
Matched Description: … 9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour …
Peptide YY (3-36)
Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
Investigational
Matched Description: … Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity …
PM02734
PM02734 is a marine derived compound. PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.
Investigational
Matched Description: … PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types …
Caprospinol
Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.
Investigational
Matched Description: … Caprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from …
NAV 1800
RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.
Investigational
Matched Description: … tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of …
Ropidoxuridine
Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.
Investigational
Matched Description: … IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of …
Ponazuril
Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.
Vet approved
Matched Description: … the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of …
Berzosertib
Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
Investigational
Matched Description: … Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous …
Sonolisib
Sonolisib has been used in trials studying the treatment of Glioblastoma, Prostate Cancer, Advanced Solid Tumors, Advanced BRAF-mutant Cancers, and Non Small Cell Lung Cancer (NSCLC), among others.
Investigational
Matched Description: … Sonolisib has been used in trials studying the treatment of Glioblastoma, Prostate Cancer, Advanced Solid …
CEP-9722
CEP-9722 is under investigation in clinical trial NCT01345357 (Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma).
Investigational
Matched Description: … CEP-9722 is under investigation in clinical trial NCT01345357 (Study of CEP-9722 in Combination With …
Fitusiran
Fitusiran is under investigation in clinical trial NCT02554773 (An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B).
Investigational
Matched Description: … Fitusiran is under investigation in clinical trial NCT02554773 (An Open-label Extension Study of an Investigational …
PF-06291874
PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus).
Investigational
Matched Description: … investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of …
Esaxerenone
Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension).
Investigational
Matched Description: … Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy …
2'-Fucosyllactose
2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-tnf Therapy).
Investigational
Matched Description: … 2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of …
Dirocaftor
Dirocaftor is under investigation in clinical trial NCT03251092 (Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis).
Investigational
Matched Description: … investigation in clinical trial NCT03251092 (Study Designed to Assess the Safety, Tolerability and PK of …
G305
G305 is a recombinant NY-ESO-1 protein plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with LV305.
Investigational
Matched Description: … G305 is an active component of CMB305 along with [LV305].[L47346] …
AMP-201
AMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.
Investigational
Matched Description: … It is under investigation for the treatment of collagen Q congenital myasthenia. …
Olokizumab
Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system. IL-6 pathway dysregulation is associated with chronic inflammation and lymphoproliferation, including in autoimmune conditions such as rheumatoid arthritis, Castleman disease, and cytokine release syndrome....
Investigational
Matched Description: … immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of …
Ciglitazone
Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.
Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market....
Experimental
Matched Description: … Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. ... Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones ... Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to …
MYR-101
MYR-101 (rAAV-Olig001-ASPA) is a recombinant adeno-associated virus (rAAV) vector-based gene therapy intended to treat Canavan disease. Canavan disease is a fatal childhood genetic disorder characterized by white matter degeneration in the brain. It is caused by a mutation in the aspartoacylase gene (ASPA), which leads to a deficiency of the...
Investigational
Matched Description: … ASPA is produced in oligodendrocytes, and participates in the metabolism of N-acetylaspartate (NAA). ... granted MYR-101 Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for the treatment of ... It is caused by a mutation in the aspartoacylase gene (_ASPA_), which leads to a deficiency of the aspartoacylase …
KD3010
KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.
Investigational
Matched Description: … small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of …
TAK-475
TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.
Investigational
Matched Description: … TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been …
CMC 001
CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
Investigational
Matched Description: … CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile …
Solabegron
Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.
Investigational
Matched Description: … Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive …
Displaying drugs 6951 - 6975 of 8030 in total